CymaBay Therapeutics - About the company
CymaBay Therapeutics is an acquired company based in Hayward (United States), founded in 1991. It operates as a Developer of therapeutics for liver and other chronic diseases. CymaBay Therapeutics has raised $277M in funding from investors like Charter Life Sciences, KBC Private Equity and Pictet Group, with last known valuation of $*****. The company has 128 active competitors, including 43 funded and 37 that have exited. Its top competitors include companies like Nimbus Therapeutics, Intercept Pharmaceuticals and Madrigal Pharmaceuticals.
Company Details
Developer of therapeutics for liver and other chronic diseases. The lead product of the company is Seladelpar is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangiti. Other products include MBX-2982 for Diabetic Hypoglycemia and CB-001 for inflammatory disorders.
- Website
- cymabay.com
- Registered Address
- Newark, California
Key Metrics
Founded Year
1991
Location
Hayward, United States
Stage
Acquired
Total Funding
$277M in 18 rounds
Latest Funding Round
Last Known Valuation
$***** as on Feb 12, 2024
Investors
Ranked
30th among 128 active competitors
Annual Revenue
$10M - $50M as on Dec 31, 2023
Employee Count
10 - 49 as on Mar 01, 2026
Similar Companies
Exit Details
Acquired by Gilead (Feb 12, 2024)
Legal entities associated with CymaBay Therapeutics
CymaBay Therapeutics is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Cymabay Therapeutics, Inc. CIN: 10254168 , United States, Active | Dec 18, 2023 | - | - | - |
CYMABAY THERAPEUTICS, INC. CIN: 943103561 , United States, Active | Dec 26, 999 | $10M - $50M (As on Dec 31, 2023) | 2 (As on Dec 31, 2024) | - |
CymaBay Therapeutics's acquisition details
Click here to take a look at CymaBay Therapeutics's acquisition in detail
Sign up to download CymaBay Therapeutics' company profile
CymaBay Therapeutics's funding and investors
CymaBay Therapeutics has raised a total funding of $277M over 18 rounds. Its first funding round was on Jul 03, 1997. Its latest funding round was a Grant (prize money) round on Aug 02, 2021 for $*****. 1 investor participated in its latest round. CymaBay Therapeutics has 26 institutional investors.
Here is the list of recent funding rounds of CymaBay Therapeutics:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Aug 02, 2021 | 8146410 | Grant (prize money) | 5546097 | 6921188 | 3179968 | 3261721 |
Jan 08, 2018 | 3248045 | Post IPO | 7695661 | 4157260 | 1971460 | |
Aug 07, 2015 | 4459579 | Unattributed | 5216400 | 4601275 | 5202599 | 9733737 |
Access funding benchmarks and valuations. Sign up today!View details of CymaBay Therapeutics's funding rounds and investors
CymaBay Therapeutics' founders and board of directors
Founder? Claim ProfileCymaBay Therapeutics' employee count trend
CymaBay Therapeutics has 10 - 49 employees as of Mar 26. Here is CymaBay Therapeutics's employee count trend over the years:
Uncover CymaBay Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
CymaBay Therapeutics's Competitors and alternates
Top competitors of CymaBay Therapeutics include Nimbus Therapeutics, Intercept Pharmaceuticals and Madrigal Pharmaceuticals. Here is the list of Top 10 competitors of CymaBay Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Nimbus Therapeutics 2009, Cambridge (United States), Series F | Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 68/100 | |
2nd | Intercept Pharmaceuticals 2002, New York City (United States), Acquired | Developer of therapeutics to treat progressive non-viral liver diseases | $121M | 67/100 | |
3rd | Madrigal Pharmaceuticals 2011, Conshohocken (United States), Acquired | Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis | $38.4M | 66/100 | |
4th |  Mammoth 2017, Brisbane (United States), Series D | Provider of molecular diagnostics platform by using CRISPR technology | $271M | 65/100 | |
5th |  Mirum Pharmaceuticals 2018, Menlo Park (United States), Public | Developer of small molecule based therapeutics to treat rare diseases | $120M | 64/100 | |
6th | Developer of a novel treatment for metabolic diseases | $83M | 63/100 | ||
7th |  Ochre Bio 2019, Oxford (United Kingdom), Series A | Developer of ribonucleic acid therapies for treating chronic liver diseases | $39.7M | 62/100 | |
8th |  Akero Therapeutics 2017, San Francisco (United States), Acquired | Developer of small molecule therapeutics for metabolic disorders | $135M | 61/100 | |
9th | Altimmune 1997, Gaithersburg (United States), Acquired | Developer of vaccines for infectious disease including influenza, hepatitis B and solid tumors | $58M | 61/100 | |
10th | Terns Pharmaceutical 2017, San Mateo (United States), Acquired | Developer of therapies for treating liver disease and cancer | $208M | 60/100 | |
30th | CymaBay Therapeutics 1991, Hayward (United States), Acquired | Developer of therapeutics for liver and other chronic diseases | $277M | 52/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on CymaBay Therapeutics's competitors? Click here to see the top ones
CymaBay Therapeutics's Investments and acquisitions
CymaBay Therapeutics has made no investments or acquisitions yet.
Reports related to CymaBay Therapeutics
Here is the latest report on CymaBay Therapeutics's geography:
News related to CymaBay Therapeutics
Filter this list•
•
•
•
Gilead’s new liver disease med continues to deliver the goods ahead of FDA verdictFierce Biotech•May 20, 2024•CymaBay Therapeutics
•
Opthea Appoints Sujal Shah To The Board Of DirectorsGlobeNewswire•Apr 04, 2024•Opthea, CymaBay Therapeutics
•
Gilead Sciences Bolsters Portfolio with CymaBay AcquisitionTipRanks•Mar 22, 2024•CymaBay Therapeutics, Gilead, Gilead
•
Halper Sadeh LLC Investigates CBAY, SCTL, EVRIBusinessFortNight•Mar 01, 2024•Everi, Societal CDMO, CymaBay Therapeutics, Halper Sadeh
•
•
CymaBay Therapeutics GAAP EPS of -$0.35 misses by $0.04Seeking Alpha•Feb 28, 2024•CymaBay Therapeutics
•
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Director Sells $191,820.00 in Stockreporter.am•Feb 17, 2024•CymaBay Therapeutics
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about CymaBay Therapeutics
Explore our recently published companies
- Blue Sky Music - Washington based, Unfunded company
- Jude Cole - Unfunded company
- Glee Gather - Karachi based, 2023 founded, Unfunded company
- GLG Puertas - Mexico based, Unfunded company
- Apolo Bass - Spain based, Unfunded company
- Handwriting Olympiad - Hyderabad based, Unfunded company
